Meaning in life and physical health: systematic review and meta-analysis

K Czekierda, A Banik, CL Park… - Health psychology …, 2017 - Taylor & Francis
This systematic review and meta-analysis aimed to clarify the associations between
meaning in life and physical health using random-effects models. Conceptualisation of …

[HTML][HTML] The Exercise and Sports Science Australia position statement: exercise medicine in cancer management

SC Hayes, RR Spence, DA Galvão… - Pensar en Movimiento …, 2023 - scielo.sa.cr
Desde la primera publicación de la declaración de consenso sobre pautas de ejercicio para
personas con cáncer, de la asociación Ejercicio y Ciencias del Deporte-Australia (ESSA …

[HTML][HTML] Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with …

HS Rugo, RS Finn, V Diéras, J Ettl, O Lipatov… - Breast cancer research …, 2019 - Springer
Purpose In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23
months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in …

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 …

JFR Robertson, IM Bondarenko, E Trishkina, M Dvorkin… - The Lancet, 2016 - thelancet.com
Background Aromatase inhibitors are a standard of care for hormone receptor-positive
locally advanced or metastatic breast cancer. We investigated whether the selective …

[HTML][HTML] Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2–positive, advanced breast …

EA Perez, C Barrios, W Eiermann, M Toi… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose Trastuzumab and pertuzumab are human epidermal growth factor receptor 2
(HER2)–targeted monoclonal antibodies, and trastuzumab emtansine (T-DM1) is an …

Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial

SM Tolaney, N Tayob, C Dang… - Journal of Clinical …, 2021 - ingentaconnect.com
PURPOSE The ATEMPT trial was designed to determine if treatment with trastuzumab
emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded …

[HTML][HTML] Trastuzumab emtansine for HER2-positive advanced breast cancer

S Verma, D Miles, L Gianni, IE Krop… - New England journal …, 2012 - Mass Medical Soc
Background Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate incorporating
the human epidermal growth factor receptor 2 (HER2)–targeted antitumor properties of …

Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis

H Haller, MM Winkler, P Klose, G Dobos… - Acta …, 2017 - Taylor & Francis
Background: The aim of this meta-analysis was to systematically update the evidence for
mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy …

[PDF][PDF] American college of sports medicine roundtable on exercise guidelines for cancer survivors

E PANEL - J. ACSM, 2010 - academia.edu
In 2009, the American Cancer Society (ACS) estimated that there were nearly 1.5 million
new cases of cancer diagnosed in the United States and just more than 500,000 people who …

乳腺癌患者生命质量测定量表(FACT-B) 中文版的修订

万崇华, 张冬梅, 汤学良, 张文莉, 李文辉, 任宏轩… - 中国心理卫生 …, 2003 - cqvip.com
目的: 修订乳腺癌生命质量测定量表FACT-B 的中文版, 并对其进行考评. 方法: 通过量表的释译,
回译及文化调适, 制定中国版的FACT-B, 并通过165 例乳腺癌患者进行的测定对量表进行考评 …